Stay updated on Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.
Latest updates to the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
- Check11 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.2%
- Check18 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe study on Pembrolizumab in combination with Olaparib for advanced BRCA-mutated or HDR-defect breast cancer has transitioned from a recruiting status to 'active, not recruiting', with updated dates and a revision to version 2.13.3.SummaryDifference2%
- Check47 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information on who can answer questions about joining the study and where it is taking place, with a revision from v2.12.2 to v2.13.2.SummaryDifference2%
- Check62 days agoChange DetectedThe website has added a 'Show less' option, while several detailed data fields and download options related to study information have been removed.SummaryDifference3%
- Check76 days agoChange DetectedThe website has been updated to version v2.12.2, adding new features for downloading study data in various formats and displaying detailed participant and study information, while removing the 'Show less' option and the previous version v2.12.1.SummaryDifference4%
Stay in the know with updates to Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.